In an interview with Applied Clinical Trials Associate Editor Don Tracy Peter Ronco, CEO, Emmes, discusses the number of ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

Separately, Rakovina Therapeutics expects to receive the first synthesized drug candidates from its second AI-driven drug ...

Labcorp forecast 2025 revenue above Wall Street estimates after reporting fourth-quarter results beat on Thursday, banking on ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

Medpace demonstrates strong financial performance and growth in the CRO market, despite facing challenges in the short term. Read why MEDP stock is a Strong Buy.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at ...

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a ...

U.S. Rep. April McClain Delaney visited Kite, a biopharmaceutical company that uses cell therapy to treat cancer, in Urbana on Thursday morning, one of several locations across her district she ...

BioSpace Senior Editor Annalee Armstrong headed to the J.P. Morgan Healthcare Conference with a months-long story idea ...